Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RYAN W JACOBS

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1114160082
CMS profile
423472
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$184,315.71

194 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Pharmacyclics LLC, An AbbVie Company $44,231.40 57
Janssen Biotech, Inc. $40,409.77 48
Secura Bio, Inc. $33,937.46 21
AstraZeneca Pharmaceuticals LP $32,297.50 30
BeiGene USA, Inc. $11,641.44 10
AbbVie Inc. $8,439.13 6
TG THERAPEUTICS, INC. $6,194.34 11
Adaptive Biotechnologies Corporation $2,895.97 4
Genentech USA, Inc. $2,250.37 5
Janssen Scientific Affairs, LLC $1,010.00 1
BeiGene, Ltd. $1,008.33 1

Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RYAN W JACOBS

NPI 1114160082 · CMS profile ID 423472

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1114160082?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RYAN W JACOBS, NPI 1114160082, CMS profile ID 423472. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1114160082?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RYAN W JACOBS, NPI 1114160082, CMS profile ID 423472. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1114160082?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RYAN W JACOBS, NPI 1114160082, CMS profile ID 423472, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1114160082?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

194 matching records · $184,315.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 194 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 194.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharmacyclics LLC, An AbbVie Company $25.0008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006833 CMS
Pharmacyclics LLC, An AbbVie Company $29.2208/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006835 CMS
Pharmacyclics LLC, An AbbVie Company $34.5008/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006837 CMS
Pharmacyclics LLC, An AbbVie Company $64.0008/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006839 CMS
Pharmacyclics LLC, An AbbVie Company $65.0008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006841 CMS
Pharmacyclics LLC, An AbbVie Company $101.2608/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006843 CMS
Pharmacyclics LLC, An AbbVie Company $229.0008/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006845 CMS
Pharmacyclics LLC, An AbbVie Company $347.6608/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006847 CMS
Pharmacyclics LLC, An AbbVie Company $716.8408/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006849 CMS
Janssen Biotech, Inc. $4,100.0008/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823631 CMS
Pharmacyclics LLC, An AbbVie Company $4,100.0008/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006809 CMS
Pharmacyclics LLC, An AbbVie Company $4,100.0008/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006811 CMS
Secura Bio, Inc. $6,270.0008/03/2021 Consulting Fee No dispute reported Delay: No
Change: CHANGED
06/30/2026 851659931 CMS
BeiGene USA, Inc. $650.0008/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846700789 CMS
Janssen Biotech, Inc. $16.0007/30/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823495 CMS
Janssen Biotech, Inc. $15.3007/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823507 CMS
Janssen Biotech, Inc. $5.3307/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823519 CMS
Pharmacyclics LLC, An AbbVie Company $111.7407/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006807 CMS
Janssen Biotech, Inc. $125.0007/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823457 CMS
Janssen Biotech, Inc. $396.4607/29/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823465 CMS
Janssen Biotech, Inc. $35.0007/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823475 CMS
Janssen Biotech, Inc. $7.5007/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823487 CMS
Janssen Biotech, Inc. $303.9607/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823603 CMS
Janssen Biotech, Inc. $25.0007/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823609 CMS
Janssen Biotech, Inc. $8.0107/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823627 CMS
Janssen Biotech, Inc. $115.3507/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823549 CMS
Janssen Biotech, Inc. $252.4807/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823561 CMS
Janssen Biotech, Inc. $22.7807/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823570 CMS
Janssen Biotech, Inc. $12.0007/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823581 CMS
Janssen Biotech, Inc. $7.3307/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823591 CMS
Janssen Biotech, Inc. $1,500.0007/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823743 CMS
Pharmacyclics LLC, An AbbVie Company $22.0107/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006803 CMS
Pharmacyclics LLC, An AbbVie Company $1,500.0007/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006805 CMS
Adaptive Biotechnologies Corporation $1,050.0007/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844349107 CMS
BeiGene USA, Inc. $85.7207/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846700791 CMS
Janssen Biotech, Inc. $1,500.0007/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787823537 CMS
Pharmacyclics LLC, An AbbVie Company $62.4607/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006799 CMS
Pharmacyclics LLC, An AbbVie Company $1,500.0007/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006801 CMS
AstraZeneca Pharmaceuticals LP $300.0006/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830089443 CMS
Pharmacyclics LLC, An AbbVie Company $1,500.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006797 CMS
Secura Bio, Inc. $8.6906/23/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 851659927 CMS
AstraZeneca Pharmaceuticals LP $4,450.0006/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829845813 CMS
AstraZeneca Pharmaceuticals LP $213.7906/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829388353 CMS
AstraZeneca Pharmaceuticals LP $125.0006/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829428317 CMS
AstraZeneca Pharmaceuticals LP $179.3706/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829640963 CMS
AstraZeneca Pharmaceuticals LP $665.7006/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829903259 CMS
AstraZeneca Pharmaceuticals LP $103.0306/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830256359 CMS
AstraZeneca Pharmaceuticals LP $1,100.0006/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829962561 CMS
Secura Bio, Inc. $56.2406/10/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 851659923 CMS
Pharmacyclics LLC, An AbbVie Company $1,500.0006/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781006795 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $340,499.11 470
PY2020 $153,588.54 180
PY2021 $184,315.71 194
PY2022 $232,028.11 215
PY2023 $198,421.28 216
PY2024 $215,690.62 177
PY2025 $218,560.94 297

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $240.00 1
PY2025 Principal investigator $2,655,472.64 116
PY2024 Recipient $2,008.18 2
PY2024 Principal investigator $2,323,263.29 33
PY2023 Principal investigator $1,527,517.76 22
PY2022 Principal investigator $192,595.11 14
PY2021 Principal investigator $154,290.11 17
PY2020 Principal investigator $89,713.40 4
PY2019 Principal investigator $43,287.92 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

117 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $550.00 12/31/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH UNION
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202404392
Principal investigator 1 BeOne Medicines Ltd. $2,080.00 12/23/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190340529
Principal investigator 1 BeOne Medicines USA, Inc. $12,117.00 12/09/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190329951
Principal investigator 1 BeOne Medicines USA, Inc. $33,150.00 12/09/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190335760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,219.89 12/04/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184268999
Principal investigator 1 BeOne Medicines Ltd. $9,395.20 12/03/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342615
Principal investigator 1 BeOne Medicines Ltd. $1,366.89 12/03/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342619
Principal investigator 1 BeOne Medicines Ltd. $546.84 12/03/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342623
Principal investigator 1 BeOne Medicines Ltd. $9,395.20 12/03/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342630
Principal investigator 1 BeOne Medicines Ltd. $10,934.28 12/03/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342634
Principal investigator 1 BeOne Medicines Ltd. $546.84 12/03/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342637
Principal investigator 1 BeOne Medicines Ltd. $1,366.89 12/03/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342642
Principal investigator 1 BeOne Medicines Ltd. $10,934.28 12/03/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342646
Principal investigator 1 BeOne Medicines Ltd. $50,304.00 12/02/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190344303
Principal investigator 1 BeOne Medicines Ltd. $736.00 11/25/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190340538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,667.82 11/25/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184264435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,345.54 11/14/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184261203
Principal investigator 1 BeOne Medicines Ltd. $1,660.00 11/12/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190340534
Principal investigator 1 BeOne Medicines Ltd. $182.28 11/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342548
Principal investigator 1 BeOne Medicines Ltd. $182.28 11/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342551
Principal investigator 1 BeOne Medicines Ltd. $455.63 11/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342555
Principal investigator 1 BeOne Medicines Ltd. $4,697.60 11/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342558
Principal investigator 1 BeOne Medicines Ltd. $4,697.60 11/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342562
Principal investigator 1 BeOne Medicines Ltd. $3,644.76 11/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342564
Principal investigator 1 BeOne Medicines Ltd. $455.63 11/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342566
Principal investigator 1 BeOne Medicines Ltd. $3,758.08 11/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342570
Principal investigator 1 BeOne Medicines Ltd. $3,758.08 11/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342574
Principal investigator 1 BeOne Medicines Ltd. $3,644.76 11/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190342578
Principal investigator 1 AstraZeneca Pharmaceuticals LP $197.25 11/10/2025 Non-covered Recipient Entity
LEVINE CANCER INST
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) No dispute reported 06/30/2026 1185554604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,245.10 11/07/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184258259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,345.54 10/29/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184253602
Principal investigator 1 BeOne Medicines USA, Inc. $8,623.00 10/28/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190329949
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,322.01 10/23/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) No dispute reported 06/30/2026 1185554606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,345.54 10/23/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184252528
Principal investigator 1 ABBVIE INC. $83,934.81 10/16/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202404338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,189.61 10/16/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184250547
Principal investigator 1 BeOne Medicines Ltd. $78,600.00 10/13/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330373
Principal investigator 1 BeOne Medicines Ltd. $100,608.00 10/13/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190330447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,069.18 10/03/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184244591
Principal investigator 1 BeOne Medicines Ltd. $3,644.76 09/25/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190344337
Principal investigator 1 BeOne Medicines Ltd. $182.28 09/25/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190344342
Principal investigator 1 BeOne Medicines Ltd. $455.63 09/25/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190344346
Principal investigator 1 BeOne Medicines Ltd. $5,582.00 09/23/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190340526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,943.23 09/18/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184240412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,838.37 09/12/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184236492
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,380.00 09/10/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES CLINICAL TRIALS OFFIC
A Modular Phase II, Single-arm, Multicenter, Open-label study to evaluate the Efficacy and Safety of AZD0486 in Subjects with Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL) No dispute reported 06/30/2026 1185554598
Principal investigator 1 BeOne Medicines Ltd. $50,304.00 09/10/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190344270
Principal investigator 1 BeOne Medicines Ltd. $2,396.00 09/02/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190340518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,928.71 08/26/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184230635
Principal investigator 1 BeOne Medicines Ltd. $3,210.00 08/12/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190327473
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 08/12/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190327475
Principal investigator 1 AstraZeneca UK Limited $17,380.00 08/07/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES CLINICAL TRIALS OFFIC
phase two open label single arm trial of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma after first line acalabrutinib progression No dispute reported 06/30/2026 1185554596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,928.37 08/07/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184226521
Principal investigator 1 ABBVIE INC. $4,204.00 08/06/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No dispute reported 06/30/2026 1202502402
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 07/31/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190337384
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,288.00 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.23 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,934.00 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $582.82 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $448.00 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,389.48 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,214.00 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,782.00 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $582.82 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,927.00 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,500.00 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,900.00 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 07/31/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222782
Principal investigator 1 BeOne Medicines Ltd. $4,377.00 07/22/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190340521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,847.80 07/22/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184217679
Principal investigator 1 BeOne Medicines Ltd. $43,737.12 07/21/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190337359
Principal investigator 1 BeOne Medicines Ltd. $33,536.00 07/21/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190344244
Principal investigator 1 BeOne Medicines Ltd. $33,536.00 07/10/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190330455
Principal investigator 1 BeOne Medicines Ltd. $33,536.00 07/10/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190330457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $916.99 07/04/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184212791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $916.99 06/24/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184210606
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,226.70 06/23/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES CLINICAL TRIALS OFFIC
Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1185554608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,711.86 06/19/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184209091
Principal investigator 1 BeOne Medicines Ltd. $14,082.00 06/17/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190331071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,437.48 06/12/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184206169
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 06/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330379
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 06/11/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330381
Principal investigator 1 BeOne Medicines Ltd. $15,733.00 05/30/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190331073
Principal investigator 1 ABBVIE INC. $2,500.00 05/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No dispute reported 06/30/2026 1202485057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,440.40 05/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184194579
Principal investigator 1 BeiGene, Ltd. $31,440.00 05/14/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323924
Principal investigator 1 AstraZeneca Pharmaceuticals LP $289.30 05/08/2025 Non-covered Recipient Entity
ATRIUM HEALTH LEVINE CANCER INSTITUTE
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) No dispute reported 06/30/2026 1185554602
Principal investigator 1 ABBVIE INC. $5,021.71 05/07/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No dispute reported 06/30/2026 1202483335
Principal investigator 1 BeiGene, Ltd. $19,900.00 04/28/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190325102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,188.03 04/28/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184190623
Principal investigator 1 BeiGene, Ltd. $18,582.00 04/22/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321442
Principal investigator 1 BeiGene, Ltd. $5,441.00 04/17/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321450
Principal investigator 1 ABBVIE INC. $12,023.00 04/16/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202404234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,667.88 04/15/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184183214
Principal investigator 1 BeiGene, Ltd. $78,600.00 04/14/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322236
Recipient F. Hoffmann-La Roche AG $240.00 04/09/2025 Covered Recipient Physician Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey No dispute reported 06/30/2026 1211538707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,570.51 04/08/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184181922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,772.50 03/25/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184178818
Principal investigator 1 ABBVIE INC. $2,410.00 03/24/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202404219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,771.58 03/11/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184170792
Principal investigator 1 BeiGene, Ltd. $31,440.00 03/04/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,757.82 03/04/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184156648
Principal investigator 1 BeiGene, Ltd. $16,990.00 02/25/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,245.10 02/25/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184155638
Principal investigator 1 ABBVIE INC. $13,067.00 02/14/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202404186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,012.75 02/11/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184153164
Principal investigator 1 Eli Lilly and Company $1,158.15 02/10/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187873685
Principal investigator 1 ABBVIE INC. $29,880.00 02/06/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No dispute reported 06/30/2026 1202446779
Principal investigator 1 BeiGene, Ltd. $47,160.00 02/06/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322128
Principal investigator 1 BeiGene, Ltd. $33,281.00 01/28/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321446
Principal investigator 1 AstraZeneca UK Limited $688,353.92 01/27/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma No dispute reported 06/30/2026 1185554600
Principal investigator 1 ABBVIE INC. $10,985.00 01/22/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202404161
Principal investigator 1 Eli Lilly and Company $427,159.98 01/22/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187871377
Principal investigator 1 BeiGene, Ltd. $7,263.00 01/21/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,590.64 01/17/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184148053
Principal investigator 1 Eli Lilly and Company $36,232.06 01/08/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187872173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,627.26 01/07/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184145716